High-dose radioimmunotherapy with yttrium 90 (90Y) ibritumomab tiuxetan with high-dose etoposide (VP-16) and cyclophosphamide (CY) followed by autologous hematopoietic cell transplant (AHCT) for poor-risk or relapsed B-cell non-Hodgkin's lymphoma (NHL):: Update of a phase I/II trial.

被引：0
|
作者：
Nademanee, A
Forman, SJ
Molina, A
Kogut, N
Fung, HC
Yamauchi, D
Anderson, AL
Smith, D
Liu, AN
Raubitschek, A
机构：
[1] City Hope Natl Med Ctr, Duarte, CA 91010 USA
[2] Biogen Idec Inc, San Diego, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6504
引用
收藏
页码：559S / 559S
页数：1
相关论文
共 50 条
  • [1] Updated results of high-dose yttrium 90 (90Y) ibritumomab tiuxetan with high-dose etoposide (VP-16) and cyclophosphamide (CY) followed by autologous hematopoietic cell transplant (AHSCT) for poor-risk or refractory B-Cell non-hodgkin's lymphoma.
    Nademanee, Auayporn
    Raubitschek, Andrew
    Molina, Arturo
    Palmer, Joycelynne
    Tsai, Ni-Chun
    Krishnan, Amrita
    Kogut, Neil
    Forman, Stephen
    [J]. BLOOD, 2007, 110 (11) : 560A - 560A
  • [2] A phase I/II trial of high-dose radioimmunotherapy (RIT) with Zevalin in combination with high-dose etoposide (VP-16) and cyclophosphamide (CY) followed by autologous stem cell transplant (ASCT) in patients with poor-risk or relapsed B-cell non-Hodgkin's lymphoma (NHL).
    Nademanee, A
    Molina, A
    Forman, SJ
    Kogut, N
    Yamauchi, D
    An, L
    White, CA
    Raubitschek, A
    [J]. BLOOD, 2002, 100 (11) : 182A - 182A
  • [3] A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma
    Nademanee, A
    Forman, S
    Molina, A
    Fung, H
    Smith, D
    Dagis, A
    Kwok, C
    Yamauchi, D
    Anderson, AL
    Falk, P
    Krishnan, A
    Kirschbaum, M
    Kogut, N
    Nakamura, R
    O'Donnell, M
    Parker, P
    Popplewell, L
    Pullarkat, V
    Rodriguez, R
    Sahebi, F
    Smith, E
    Snyder, D
    Stein, A
    Spielberger, R
    Zain, J
    White, C
    Raubitschek, A
    [J]. BLOOD, 2005, 106 (08) : 2896 - 2902
  • [4] Multicenter phase II trial of 90Y-Ibritumomab tiuxetan with high-dose chemotherapy (busulfan/cyclophosphamide/etoposide) followed by autologous stem cell transplantation in relapsed, refractoried, or high-risk B-cell NHL
    Kang, Byung Woog
    Jo, Jae-Cheol
    Kim, Shin
    Jang, Geundoo
    Lee, Sung Sook
    Sym, Sun Jin
    Ryu, Jin-Sook
    Kim, Won Seog
    Yoon, Sung Soo
    Suh, Cheolwon
    [J]. BLOOD, 2007, 110 (11) : 569A - 569A
  • [5] Multicentre phase II trial of 90Y-ibritumomab tiuxetan with high-dose chemotherapy (busulfan/cyclophosphamide/etoposide) followed by autologous stem cell transplantation in relapsed, refractory, or high-risk B-cell NHL
    Kang, B. W.
    Kim, S.
    Cho, Y. H.
    Ryu, J. -S.
    Kim, W. S.
    Yoon, S. S.
    Suh, C.
    [J]. BONE MARROW TRANSPLANTATION, 2008, 41 : S248 - S248
  • [6] Phase I trial of 90Y-ibritumomab tiuxetan in patients with relapsed B-cell non-Hodgkin's lymphoma following high-dose chemotherapy and autologous stem cell transplantation
    Vose, Julie M.
    Bierman, Philip J.
    Loberiza, Fausto R., Jr.
    Bociek, Robert G.
    Matso, Daniel
    Armitage, James O.
    [J]. LEUKEMIA & LYMPHOMA, 2007, 48 (04) : 683 - 690
  • [7] Yttrium-90 ibritumomab tiuxetan combined with high-dose beam chemotherapy and autologous stem cell transplantation for relapsed/refractory B-cell non-Hodgkin's lymphoma
    Shimabukuro-Vornhagen, A.
    Josting, A.
    Scheid, C.
    Huebel, K.
    Boldt, F.
    Dietlein, M.
    Engert, A.
    Schnell, R.
    [J]. ANNALS OF ONCOLOGY, 2008, 19 : 241 - 242
  • [8] Yttrium-90 ibritumomab tiuxetan combined with high-dose BEAM chemotherapy and autologous stem cell transplantation for relapsed/refractory B-cell non-Hodgkin's lymphoma
    Shimabukuro-Vornhagen, A.
    Josting, A.
    Huebel, K.
    Scheid, C.
    Dietlein, M.
    Engert, A.
    Schnell, R.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [9] Dose finding trial of yttrium 90 (90Y) ibriturnomab tiuxetan with autologous stem cell transplantation (ASCT) in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL).
    Flinn, IW
    Kahl, BS
    Frey, E
    Bianco, JA
    Hammes, RJI
    Billing, LS
    Swinnen, LJ
    Sgouros, G
    Wahl, RL
    [J]. BLOOD, 2004, 104 (11) : 256A - 256A
  • [10] Long-Term Results of Autologous Hematopoietic Stem-Cell Transplantation After High-Dose 90Y-Ibritumomab Tiuxetan for Patients With Poor-Risk Non-Hodgkin Lymphoma Not Eligible for High-Dose BEAM
    Devizzi, Liliana
    Guidetti, Anna
    Seregni, Ettore
    Passera, Roberto
    Maccauro, Marco
    Magni, Michele
    Testi, Adele
    Di Nicola, Massimo
    Tarella, Corrado
    Matteucci, Paola
    Viviani, Simonetta
    Ruella, Marco
    Carlo-Stella, Carmelo
    Chiesa, Carlo
    Cox, Maria Cristina
    Bombardieri, Emilio
    Gianni, Alessandro M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (23) : 2974 - 2976
12345